Evidence map›Paper›PMID 41337860›Full record

Trial reportESMO open2025

Streptozotocin plus 5-fluorouracil followed by everolimus or the reverse sequence in patients with advanced pancreatic neuroendocrine tumors (SEQTOR-GETNE phase III study): a randomized clinical trial.

J Capdevila, S Tafuto, M Krogh, A Teulé, R Garcia-Carbonero, H-J Klümpen, B Cremer, I Sevilla, B Eriksson, E Tabaksblat and 32 more

Abstract readRandomized Controlled TrialClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in ESMO open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

42 authors.

J CapdevilaDepartment of Medical Oncology, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
S TafutoSarcomas and Rare Tumors Unit, Istituto Nazionale Tumori IRCCS, Fondazione 'G.Pascale', Naples, Italy.
M KroghMedical Oncology Department, Odense University Hospital, Odense, Denmark.
A TeuléMedical Oncology Department, Oncobell Program, IDIBELL, Institut Català d'Oncologia (ICO) Hospital Duran i Reynals, Barcelona, Spain; Clinical Sciences Department, Bellvitge Campus, University of Barcelona, CIBERONC, Barcelona, Spain.
R Garcia-CarboneroMedical Oncology Department, Hospital Universitario 12 de Octubre, Imas12, UCM, Madrid, Spain.
H-J KlümpenMedical Oncology Department, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
B CremerMedical Oncology Department, Universitätsklinikum Köln (AöR), Köln, Germany.
I SevillaMedical Oncology Department, Investigación Clínica y Traslacional en Cáncer, Instituto de Investigaciones Biomédicas de Málaga (IBIMA), Hospital Universitario Virgen de la Victoria de Málaga, Málaga, Spain.
B ErikssonEndocrine Oncology Department, Uppsala University Hospital, Uppsala, Sweden.
E TabaksblatMedical Oncology Department, Aarhus University Hospital, ENETS Center of Excellence, Aarhus, Denmark.
J-P MetgesMedical Oncology Department, Brest Hôpital Augustin Morvan, Institut de Cancero-Hemato, Brest, France.
N S ReedMedical Oncology Department, Beatson Oncology Centre, Glasgow, UK.
J SchraderMedical Oncology Department, Hamburg Medizinische Klinik und Poliklinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
V NavarroClinical Research Unit, Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Barcelona, Spain.
V ValentíMedical Oncology Department, Oncobell Program, IDIBELL, Institut Català d'Oncologia (ICO) Hospital Duran i Reynals, Barcelona, Spain; Clinical Sciences Department, Bellvitge Campus, University of Barcelona, CIBERONC, Barcelona, Spain.
J HernandoDepartment of Medical Oncology, Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain; Neuroendocrine and Endocrine Tumor Translational Research Program (NET-VHIO), Vall Hebron Institute of Oncology (VHIO), Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
A M ColaoSarcomas and Rare Tumors Unit, Istituto Nazionale Tumori IRCCS, Fondazione 'G.Pascale', Naples, Italy.
L VestermarkMedical Oncology Department, Odense University Hospital, Odense, Denmark.
C CarnaghiMedical Oncology Department, Humanitas Cancer Center, Milano, Italy.
U P KniggeDepartment of Endocrinology, ENETS Center of Excellence, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
P Jimenez-FonsecaMedical Oncology Department, Hospital Universitario Central de Asturias, ISPA, Oviedo, Spain.
M BenaventMedical Oncology Department, University Hospital Virgen del Rocío, Seville Institute of Biomedicine (IBIS), Seville, Spain.
J de Vos-GeelenMedical Oncology Department, GROW - Research Institute for Oncology & Reproduction, Maastricht University Medical Centre, Maastricht, The Netherlands.
M VeneritoDepartment of Gastroenterology, Hepatology and Infectious Diseases, Universitätsklinikum Magdeburg A. ö. R, Magdeburg, Germany.
A Von WerderMedical Oncology Department, München rechts der Isar II, Medizinische Klinik und Poliklinik, München, Germany.
H JannMedical Oncology Department, Berlin Charité Universitätsmedizin, Berlin, Germany.
A RinkeDepartment of Gastroenterology, Marburg Universitätsklinikum Giessen und Marburg, Marburg, Germany; Philipps University Marburg, Marburg, Germany.
D SmithMedical Oncology Department, Bordeaux University Hospital-CHU Bordeaux, Hôpital Saint-André, Bordeaux, France.
D HörschMedical Oncology Department, Bad Berka ChA Klinik für Innere Medizin, Bad Berka, Germany.
N StarlingMedical Oncology Department, The Royal Marsden NHS Foundation Trust, Sutton, UK.
P RuszniewskiMedical Oncology Department, Université Paris Cité, Beaujon Hospital, APHP, Clichy, France.
E BaudinMedical Oncology Department, Villejuif Institut Gustave-Roussy, Paris, France.
F-X Caroli-BoscMedical Oncology Department, Unité Transversale de Thérapeutiques Innovantes en Oncologie Médicale (UTTIOM), Centre Hospitalier Universitaire (CHU) Angers, Angers, France.
J L ManzanoMedical Oncology Department, Institut Català d'Oncologia (ICO), ICO-Badalona, H. Germans Trias i Pujol, Badalona, Barcelona, Spain.
M MartínMedical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
A ScarpaARC-Net Research Center, University and Hospital Trust of Verona, Verona, Italy; Department of Diagnostics and Public Health, Section of Pathology, and Department of Engineering for Innovative Medicine, University of Verona, Verona, Italy.
R T LawlorARC-Net Research Center, University and Hospital Trust of Verona, Verona, Italy; Department of Diagnostics and Public Health, Section of Pathology, and Department of Engineering for Innovative Medicine, University of Verona, Verona, Italy.
C RagulanDivision of Molecular Pathology, Institute of Cancer Research, London, UK.
H PsDivision of Molecular Pathology, Institute of Cancer Research, London, UK.
A SadanandamDivision of Molecular Pathology, Institute of Cancer Research, London, UK.
A Carmona-BayonasMedical Oncology Department, Hospital General Universitario Morales Meseguer, UMU, IMIB, Murcia, Spain.
R SalazarMedical Oncology Department, Oncobell Program, IDIBELL, Institut Català d'Oncologia (ICO) Hospital Duran i Reynals, Barcelona, Spain; Clinical Sciences Department, Bellvitge Campus, University of Barcelona, CIBERONC, Barcelona, Spain. Electronic address: ramonsalazar@iconcologia.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEverolimus or streptozotocin plus 5-fluorouracil (STZ/5-FU) are approved treatments for patients with pancreatic neuroendocrine tumors (panNETs). The SEQTOR trial aimed to assess the optimal treatment sequence. PATIENTS AND

methodsSEQTOR was an international, open-label, randomized, crossover, phase III trial that recruited adults with unresectable or metastatic, advanced, well-differentiated panNET. Patients received 10 mg/day of everolimus followed upon progression by STZ/5-FU; or the reverse sequence. The primary endpoint was the 35-month progression-free survival (PFS) rate after first- and second-line treatment; however, due to slow accrual and longer survival, it was changed to the 12-month PFS rate following first-line treatment (12-mPFS

resultsPatients were randomized to everolimus (n = 72) or STZ/5-FU (n = 69) first. The 12-mPFS

conclusionSTZ/5-FU and everolimus were not statistically different in PFS rates, but STZ/5-FU achieved higher response rates.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsEverolimusFluorouracilNeuroendocrine TumorsPancreatic NeoplasmsStreptozocinAdultAgedFemaleHumansMaleMiddle AgedProgression-Free SurvivalEverolimusFluorouracilStreptozocin5-fluorouraciladvanced pancreatic neuroendocrine neoplasmeverolimuspanNETsequential strategystreptozotocin

Identifiers

PMID41337860
PMCPMC12720089

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.